HerTACs Enable Tumor‐Selective Lysosomal Degradation of Membrane and Extracellular Proteins via HER2 Trafficking
Angewandte Chemie International Edition · 06.10.2025 · 64 (41)
DOI: 10.1002/anie.202511467 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 21.08.2025. Verfasst von Shipeng He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine, Shanghai University, 99 Shangda Road, Shanghai, 200444, P.R. China. Hauptthemen laut MEDLINE: Lysosomes, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Agents, Peptides. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Shanghai Rising-Star Program.
Abstract (Originalsprache)
Targeting extracellular and membrane proteins for degradation remains a frontier challenge in the field of targeted protein degradation (TPD), largely due to the intracellular confinement of existing proteolysis systems and reliance on bulky biologics. Here, we develop a novel TPD platform, human epidermal growth factor receptor 2 (HER2)‐targeted lysosome‐tethering chimeras (HerTACs), which co‐opts the tumor overexpressed, endocytic, and lysosomal trafficking capability of HER2. Starting from the HER2‐binding peptide LTVSPWY, we engineered the first‐generation HerTAC ( LP ), a conjugate of the HER2‐binding peptide and a PD‐L1 ligand, to degrade programmed death ligand 1 (PD‐L1) in HER2‐positive cells. Guided by AlphaFold modeling and alanine scanning, we developed a stapled peptide‐based HerTAC ( L 2,5 P ) with enhanced degradative efficacy (DC 50 = 156 nM), stability, and pharmacokinetics. HerTAC L 2,5 P showed potent antitumor activity and low systemic toxicity in HER2 + breast cancer animal models. The HerTAC strategy was further extended to other clinically relevant inaccessible membrane and extracellular targets (i.e., V‐domain Ig suppressor of T cell activation [VISTA] and macrophage migration inhibitory factor [MIF]), highlighting its generality and broad applicability. This work establishes a tumor‐selective, lysosome‐directed TPD strategy that expands the druggable proteome and offers a clinically transformable approach for precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Translational Medicine, Shanghai University, 99 Shangda Road, Shanghai, 200444, P.R. China.
- Department The Center for Basic Research and Innovation of Medicine and Pharmacy (MOE), School of Pharmacy, Second Military Medical University (Naval Medical University), Address 2325 Guohe Road, Shanghai, 200433, P.R.…
ORCID-Profile: Chunquan Sheng
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Shanghai Rising-Star Program
Zitieren
APA
He, S., Huang, W., Zhu, Y., Gao, F., Fang, Y., Zhu, J., Bao, Y., Dong, G., & Sheng, C. (2025). HerTACs Enable Tumor‐Selective Lysosomal Degradation of Membrane and Extracellular Proteins via HER2 Trafficking. Angewandte Chemie International Edition, 64(41). https://doi.org/10.1002/anie.202511467
Vancouver
He S, Huang W, Zhu Y, Gao F, Fang Y, Zhu J, et al. HerTACs Enable Tumor‐Selective Lysosomal Degradation of Membrane and Extracellular Proteins via HER2 Trafficking. Angewandte Chemie International Edition. 2025;64(41). doi:10.1002/anie.202511467
BibTeX
@article{He2025,
author = {He, Shipeng and Huang, Wenjing and Zhu, Yaojin and Gao, Fei and Fang, Yuxin and Zhu, Jiayi and Bao, Yuhan and Dong, Guoqiang and Sheng, Chunquan},
title = {HerTACs Enable Tumor‐Selective Lysosomal Degradation of Membrane and Extracellular Proteins via HER2 Trafficking},
journal = {Angewandte Chemie International Edition},
year = {2025},
volume = {64},
number = {41},
doi = {10.1002/anie.202511467}
}
EUVIMED